Kandace Gollomp1, Michele P Lambert, Mortimer Poncz. 1. Division of Hematology, Children's Hospital of Philadelphia and the Department of Pediatrics, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Abstract
PURPOSE OF REVIEW: Donor-derived platelets have proven to be of hemostatic value in many clinical settings. There is a fear that the need for platelets may outgrow the donor pool in first-world countries. Moreover, there are other challenges with donor platelets that add to the impetus to find an alternative platelet source, especially after the megakaryocyte cytokine thrombopoietin was identified. Megakaryocytes have since been differentiated from numerous cell sources and the observed released platelet-like particles (PLPs) have led to calls to develop such products for clinical use. The development of megakaryocytes from embryonic stem cell also supported the concept of developing nondonor-based platelets. RECENT FINDINGS: Several groups have claimed that nondonor-based platelets derived from in-vitro grown megakaryocytes may soon become available to supplement or replace donor-derived products, but their number and quality has been wanting. A possible alternative of directly infusing megakaryocytes that release platelets in the lungs - similar to that recently shown for endogenous megakaryocytes - has been proposed. SUMMARY: This present review will describe the present state-of-the-art in generating and delivering nondonor-derived platelets. Progress has been slow, but advances in our ability to generate human megakaryocytes in culture, generate PLPs from these cells, and test the functionality of the resultant platelets in vitro and in vivo have identified important remaining challenges and raised alternative potential solutions.
PURPOSE OF REVIEW: Donor-derived platelets have proven to be of hemostatic value in many clinical settings. There is a fear that the need for platelets may outgrow the donor pool in first-world countries. Moreover, there are other challenges with donor platelets that add to the impetus to find an alternative platelet source, especially after the megakaryocyte cytokine thrombopoietin was identified. Megakaryocytes have since been differentiated from numerous cell sources and the observed released platelet-like particles (PLPs) have led to calls to develop such products for clinical use. The development of megakaryocytes from embryonic stem cell also supported the concept of developing nondonor-based platelets. RECENT FINDINGS: Several groups have claimed that nondonor-based platelets derived from in-vitro grown megakaryocytes may soon become available to supplement or replace donor-derived products, but their number and quality has been wanting. A possible alternative of directly infusing megakaryocytes that release platelets in the lungs - similar to that recently shown for endogenous megakaryocytes - has been proposed. SUMMARY: This present review will describe the present state-of-the-art in generating and delivering nondonor-derived platelets. Progress has been slow, but advances in our ability to generate human megakaryocytes in culture, generate PLPs from these cells, and test the functionality of the resultant platelets in vitro and in vivo have identified important remaining challenges and raised alternative potential solutions.
Authors: Christian A Di Buduo; Lindsay S Wray; Lorenzo Tozzi; Alessandro Malara; Ying Chen; Chiara E Ghezzi; Daniel Smoot; Carla Sfara; Antonella Antonelli; Elise Spedden; Giovanna Bruni; Cristian Staii; Luigi De Marco; Mauro Magnani; David L Kaplan; Alessandra Balduini Journal: Blood Date: 2015-01-09 Impact factor: 22.113
Authors: Dubravka Kufrin; Don E Eslin; Khalil Bdeir; Juan-Carlos Murciano; Alice Kuo; M Anna Kowalska; Jay L Degen; Bruce S Sachais; Douglas B Cines; Mortimer Poncz Journal: Blood Date: 2003-04-10 Impact factor: 22.113
Authors: Yuhuan Wang; Vincent Hayes; Danuta Jarocha; Xiuli Sim; Dawn C Harper; Rudy Fuentes; Spencer K Sullivan; Paul Gadue; Stella T Chou; Beverly J Torok-Storb; Michael S Marks; Deborah L French; Mortimer Poncz Journal: Blood Date: 2015-04-07 Impact factor: 22.113
Authors: Brandy Pickens; Yingying Mao; Dengju Li; Don L Siegel; Mortimer Poncz; Douglas B Cines; X Long Zheng Journal: Blood Date: 2015-03-23 Impact factor: 22.113
Authors: Helen V Yarovoi; Dubravka Kufrin; Don E Eslin; Michael A Thornton; Sandra L Haberichter; Qizhen Shi; Hua Zhu; Rodney Camire; Steve S Fakharzadeh; M Anna Kowalska; David A Wilcox; Bruce S Sachais; Robert R Montgomery; Mortimer Poncz Journal: Blood Date: 2003-07-24 Impact factor: 22.113
Authors: Massiel Chavez Stolla; Seana C Catherman; Paul D Kingsley; R Grant Rowe; Anne D Koniski; Katherine Fegan; Leah Vit; Kathleen E McGrath; George Q Daley; James Palis Journal: Blood Adv Date: 2019-01-08
Authors: Bijender Kumar; Vahid Afshar-Kharghan; Mayela Mendt; Robert Sackstein; Mark R Tanner; Uday Popat; Jeremy Ramdial; May Daher; Juan Jimenez; Rafet Basar; Luciana Melo Garcia; Mayra Shanley; Mecit Kaplan; Xinhai Wan; Vandana Nandivada; Francia Reyes Silva; Vernikka Woods; April Gilbert; Ricardo Gonzalez-Delgado; Sunil Acharya; Paul Lin; Hind Rafei; Pinaki Prosad Banerjee; Elizabeth J Shpall Journal: Front Immunol Date: 2022-09-20 Impact factor: 8.786
Authors: Kamaleldin E Elagib; Ashton Brock; Cara M Clementelli; Goar Mosoyan; Lorrie L Delehanty; Ranjit K Sahu; Alexandra Pacheco-Benichou; Corinne Fruit; Thierry Besson; Stephan W Morris; Koji Eto; Chintan Jobaliya; Deborah L French; Paul Gadue; Sandeep Singh; Xinrui Shi; Fujun Qin; Robert Cornelison; Hui Li; Camelia Iancu-Rubin; Adam N Goldfarb Journal: J Clin Invest Date: 2022-10-03 Impact factor: 19.456